Unusual Options Activity In Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases.

Big Pharm is in search for the next $1 billion drug as most disease categories have been conquered. One exception is gene therapy. Gene therapy is treatments designed to replace faulty genes with healthy ones.

In 2018 Novartis acquired gene therapy player AveXis for $8.7 billion. On Feb 22nd, Roche said it will buy Spark Therapeutics (NASDAQ:ONCE) for $4.3 billion, or $114.50 per share, a premium of about 122%.

Recently, Sarepta Therapeutics (NASDAQ:SRPT) acquired a

About the author: TIMM Trader

Uniting Experts & Novices for Mutual Profit!